How to Read an NGS Cancer Report
Variants, biomarkers, evidence tiers and the questions to take to your oncologist
Written byTeam Oncquest
DJ
Reviewer
Reviewer profile
Dr. Jasmine Kaur
Dr. Jasmine Kaur is a Consultant in R&D in the Molecular Biology and Genomics Department at Oncquest Laboratories.
10
Articles reviewedof 11 in the library
4
Topics coveredAcross published contributions
Oct 202026
Latest article updatePublished content
About
Background
Dr. Jasmine Kaur is a Consultant in R&D in the Molecular Biology and Genomics Department at Oncquest Laboratories. She holds a PhD in Biotechnology from Jamia Hamdard, New Delhi, and an MPhil, with more than seven years of post-PhD experience in molecular diagnostics. Her work includes developing, standardising and validating clinically relevant molecular assays and analysing genomic biomarkers for medical testing.
Topics covered
Review record
Reviewed Articles 10
10 articles.
CGP 550 Plus and CGP 270 Plus Cancer Testing
How the panels differ and how to read a comprehensive genomic profile
10 min read
Written byTeam Oncquest
MammaPrint and BluePrint Breast Cancer Testing
What the tests measure and how results support treatment discussions
9 min read
Written byTeam Oncquest
Variant Allele Frequency in Cancer NGS Reports
What VAF measures, why percentages vary and what they cannot tell you alone
8 min read
Written byTeam Oncquest
Gene Fusions in Cancer
What a fusion means, how testing finds it and why the method matters
8 min read
Written byTeam Oncquest
Molecular Subtypes of Breast Cancer
Luminal A, Luminal B, HER2 and Basal types—and how they differ from routine pathology labels
8 min read
Written byTeam Oncquest
Understanding MammaPrint Results
Risk categories, the MammaPrint Index and what to discuss when the report arrives
9 min read
Written byTeam Oncquest
MSI Testing in Cancer: MSI-High, PCR, IHC and Results
Understand MSI-high, MSI-low, MSS and dMMR, how PCR, IHC and NGS testing work, and how cancer biomarker reports are interpreted.
15 min read
Written byTeam Oncquest
Hereditary Breast and Ovarian Cancer Syndrome: Genes, Risk and Testing
Understand HBOC, BRCA1/2 and other genes, inheritance, counselling, test choices and why a negative BRCA result may not exclude hereditary risk.
18 min read
Written byTeam Oncquest
BRCA1 vs BRCA2 Mutations: Cancer Risks and Test Results
Understand BRCA1 and BRCA2, germline versus somatic findings, pathogenic variants, VUS results and genetic counselling in India.
Written byTeam Oncquest